Literature DB >> 12871832

The critical role of leukotriene B4 in antigen-induced mechanical hyperalgesia in immunised rats.

Joice Maria Cunha1, Daniela Sachs, Cláudio Azevedo Canetti, Stephen Poole, Sérgio Henrique Ferreira, Fernando Queiroz Cunha.   

Abstract

1. We investigated the mediators responsible for mechanical hypersensitivity induced by antigen challenge in rats immunised with ovalbumin (OVA). 2. Challenge with OVA (12.5-100 micro g, intraplantar) caused a dose- and time-dependent mechanical hypersensitivity, which peaked 3 h after, decreased thereafter and reached control levels 24 h later. 3. Levels of TNFalpha, IL-1beta and cytokine-induced neutrophil chemoattractant 1 (CINC-1) were increased in paw skin after antigen challenge. 4. OVA-evoked hypersensitivity was partially inhibited (about 51%) by pretreatment with anti-TNFalpha, IL-1beta and IL-8 sera or with IL-1 receptor antagonist (IL-1ra), but not anti-NGF serum. Pretreatment with thalidomide (45 mg kg(-1)) or pentoxifylline (100 mg kg(-1)) also partially inhibited the hypersensitivity at 1-3 h after challenge. 5. Pretreatment with indomethacin (5 mg kg(-1)) or atenolol (1 mg kg(-1)) reduced the OVA-induced hypersensitivity at 1 and 3 h, but not at 5 h after challenge, while the combination of B(1) and B(2) bradykinin receptor antagonists was ineffective over the same times. 6. Pretreatment with MK886 (5-lipoxygenase-activating protein inhibitor, 3 mg kg(-1)), CP 105696 (LTB(4) receptor antagonist; 3 mg kg(-1)) or dexamethasone (0.5 mg kg(-1)) inhibited the hypersensitivity from 1 to 5 h. Furthermore, LTB(4) levels were increased in the paw skin of challenged rats. 7. In conclusion, our results suggest that the TNFalpha-, IL-1beta- and CINC-1-driven release of prostaglandins, sympathetic amines and LTB(4) mediates the first 3 h of mechanical hypersensitivity induced by antigen challenge in rats. At 5 h after OVA administration, although TNFalpha has some role, LTB(4) is the critical nociceptive mediator.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12871832      PMCID: PMC1573940          DOI: 10.1038/sj.bjp.0705346

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  74 in total

1.  Involvement of resident macrophages and mast cells in the writhing nociceptive response induced by zymosan and acetic acid in mice.

Authors:  R A Ribeiro; M L Vale; S M Thomazzi; A B Paschoalato; S Poole; S H Ferreira; F Q Cunha
Journal:  Eur J Pharmacol       Date:  2000-01-03       Impact factor: 4.432

2.  Tumor necrosis factor-alpha in synovial fluid and plasma from patients with chronic connective tissue disease and its relation to temporomandibular joint pain.

Authors:  S Nordahl; P Alstergren; S Kopp
Journal:  J Oral Maxillofac Surg       Date:  2000-05       Impact factor: 1.895

3.  A proinflammatory role for IL-18 in rheumatoid arthritis.

Authors:  J A Gracie; R J Forsey; W L Chan; A Gilmour; B P Leung; M R Greer; K Kennedy; R Carter; X Q Wei; D Xu; M Field; A Foulis; F Y Liew; I B McInnes
Journal:  J Clin Invest       Date:  1999-11       Impact factor: 14.808

4.  Chronic hypersensitivity for inflammatory nociceptor sensitization mediated by the epsilon isozyme of protein kinase C.

Authors:  K O Aley; R O Messing; D Mochly-Rosen; J D Levine
Journal:  J Neurosci       Date:  2000-06-15       Impact factor: 6.167

5.  Mig, GRO alpha and RANTES messenger RNA expression in lining layer, infiltrates and different leucocyte populations of synovial tissue from patients with rheumatoid arthritis, psoriatic arthritis and osteoarthritis.

Authors:  A König; V Krenn; A Toksoy; N Gerhard; R Gillitzer
Journal:  Virchows Arch       Date:  2000-05       Impact factor: 4.064

6.  Analgesic effect of thalidomide on inflammatory pain.

Authors:  R A Ribeiro; M L Vale; S H Ferreira; F Q Cunha
Journal:  Eur J Pharmacol       Date:  2000-03-10       Impact factor: 4.432

7.  The pivotal role of tumour necrosis factor alpha in the development of inflammatory hyperalgesia.

Authors:  F Q Cunha; S Poole; B B Lorenzetti; S H Ferreira
Journal:  Br J Pharmacol       Date:  1992-11       Impact factor: 8.739

8.  Nerve growth factor-induced hyperalgesia in the neonatal and adult rat.

Authors:  G R Lewin; A M Ritter; L M Mendell
Journal:  J Neurosci       Date:  1993-05       Impact factor: 6.167

9.  Bradykinin release of TNF-alpha plays a key role in the development of inflammatory hyperalgesia.

Authors:  S H Ferreira; B B Lorenzetti; F Q Cunha; S Poole
Journal:  Agents Actions       Date:  1993

10.  Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation.

Authors:  A L Moreira; E P Sampaio; A Zmuidzinas; P Frindt; K A Smith; G Kaplan
Journal:  J Exp Med       Date:  1993-06-01       Impact factor: 14.307

View more
  10 in total

1.  Leukotriene b4 and its metabolites prime the neutrophil oxidase and induce proinflammatory activation of human pulmonary microvascular endothelial cells.

Authors:  John C Eun; Ernest E Moore; Anirban Banerjee; Marguerite R Kelher; Samina Y Khan; David J Elzi; Nathan J D McLaughlin; Christopher C Silliman
Journal:  Shock       Date:  2011-03       Impact factor: 3.454

2.  Proposal to use pentoxifylline and Lyprinol therapy for chronic inflammatory diseases.

Authors:  S H Ferreira
Journal:  Inflammopharmacology       Date:  2005       Impact factor: 4.473

3.  Glutamine depletion potentiates leucocyte-dependent inflammatory events induced by carrageenan or Clostridium difficile toxin A in rats.

Authors:  Silvia B Nascimento; Romualdo B Sousa; Marcos Jullian B Martins; Antoniella Souza Gomes; Marcellus Henrique L P Souza; Richard L Guerrant; Fernando Q Cunha; Ronaldo A Ribeiro; Gerly A C Brito
Journal:  Immunology       Date:  2005-11       Impact factor: 7.397

4.  GluA1 in Central Amygdala Promotes Opioid Use and Reverses Inhibitory Effect of Pain.

Authors:  Yuan-Yuan Hou; You-Qing Cai; Zhizhong Z Pan
Journal:  Neuroscience       Date:  2019-12-19       Impact factor: 3.590

5.  Role of complement C5a in mechanical inflammatory hypernociception: potential use of C5a receptor antagonists to control inflammatory pain.

Authors:  E Ting; A T G Guerrero; T M Cunha; W A Verri; S M Taylor; T M Woodruff; F Q Cunha; S H Ferreira
Journal:  Br J Pharmacol       Date:  2007-12-17       Impact factor: 8.739

6.  IL-15 mediates immune inflammatory hypernociception by triggering a sequential release of IFN-gamma, endothelin, and prostaglandin.

Authors:  Waldiceu A Verri; Thiago M Cunha; Carlos A Parada; Xiao-qing Wei; Sérgio Henrique Ferreira; Foo Y Liew; Fernando Q Cunha
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-09       Impact factor: 11.205

7.  Inhibition of 5-lipoxygenase alleviates graft-versus-host disease.

Authors:  Barbara Maximino Rezende; Rayssa Maciel Athayde; William Antônio Gonçalves; Carolina Braga Resende; Priscila Teles de Tolêdo Bernardes; Denise Alves Perez; Lísia Esper; Alesandra Côrte Reis; Milene Alvarenga Rachid; Marina Gomes Miranda E Castor; Thiago Mattar Cunha; Fabiana Simão Machado; Mauro Martins Teixeira; Vanessa Pinho
Journal:  J Exp Med       Date:  2017-09-25       Impact factor: 14.307

8.  Diverse characters of Brennan's paw incision model regarding certain parameters in the rat.

Authors:  Rahul Kumar; Shivani Gupta; Mayank Gautam; Saroj Kaler Jhajhria; Subrata Basu Ray
Journal:  Korean J Pain       Date:  2019-07-01

9.  Neutrophils promote CXCR3-dependent itch in the development of atopic dermatitis.

Authors:  Carolyn M Walsh; Rose Z Hill; Jamie Schwendinger-Schreck; Jacques Deguine; Emily C Brock; Natalie Kucirek; Ziad Rifi; Jessica Wei; Karsten Gronert; Rachel B Brem; Gregory M Barton; Diana M Bautista
Journal:  Elife       Date:  2019-10-21       Impact factor: 8.140

10.  Icariin Ameliorates Lower Back Pain in Rats via Suppressing the Secretion of Cytokine-Induced Neutrophil Chemoatractant-1.

Authors:  Jitian Li; Manli Luo; Shaochun Wang; Guoguo Jin; Zongchang Han; Yan Ma; Guoqing Tang; Zhiping Guo
Journal:  Biomed Res Int       Date:  2020-08-05       Impact factor: 3.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.